GILD Share Price

Open 72.34 Change Price %
High 73.13 1 Day 0.68 0.94
Low 71.95 1 Week 0.28 0.39
Close 72.70 1 Month -5.14 -6.60
Volume 9899050 1 Year -29.92 -29.16
52 Week High 104.79
52 Week Low 70.83
GILD Important Levels
Resistance 2 73.79
Resistance 1 73.34
Pivot 72.59
Support 1 72.06
Support 2 71.61
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 5
As on 9th Dec 2016 GILD Share Price closed @ 72.70 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 83.90 & Strong Sell for SHORT-TERM with Stoploss of 75.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for December
1st Target up-side 78.41
2nd Target up-side 81.7
3rd Target up-side 84.99
1st Target down-side 69.03
2nd Target down-side 65.74
3rd Target down-side 62.45
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.